124 related articles for article (PubMed ID: 9682337)
1. Inhibition of rotavirus infection in vitro and in vivo by a synthetic peptide from VP4.
Ijaz MK; Nur-E-Kamal MS; Dar FK; Uduman S; Redmond MJ; Attah-Poku SK; Dent D; Babiuk LA
Vaccine; 1998; 16(9-10):916-20. PubMed ID: 9682337
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a synthetic peptide mimicking trypsin-cleavage site of rotavirus VP4.
Ijaz MK; Alkarmi TO; Sabara MI; Frenchick PJ; el Mekki AA; Naiem M; Nur-e-Kamal MS; Frossard PM; Dar FK; Babiuk LA
Comp Immunol Microbiol Infect Dis; 1995 Jun; 18(3):145-60. PubMed ID: 7554816
[TBL] [Abstract][Full Text] [Related]
3. Priming and induction of anti-rotavirus antibody response by synthetic peptides derived from VP7 and VP4.
Ijaz MK; Alkarmi TO; el-Mekki AW; Galadari SH; Dar FK; Babiuk LA
Vaccine; 1995 Mar; 13(4):331-8. PubMed ID: 7793126
[TBL] [Abstract][Full Text] [Related]
4. Heterotypic passive protection induced by synthetic peptides corresponding to VP7 and VP4 of bovine rotavirus.
Ijaz MK; Attah-Poku SK; Redmond MJ; Parker MD; Sabara MI; Frenchick P; Babiuk LA
J Virol; 1991 Jun; 65(6):3106-13. PubMed ID: 1851871
[TBL] [Abstract][Full Text] [Related]
5. Assembly of recombinant rotavirus proteins into virus-like particles and assessment of vaccine potential.
Redmond MJ; Ijaz MK; Parker MD; Sabara MI; Dent D; Gibbons E; Babiuk LA
Vaccine; 1993; 11(2):273-81. PubMed ID: 8382422
[TBL] [Abstract][Full Text] [Related]
6. Expression and characterization of a novel truncated rotavirus VP4 for the development of a recombinant rotavirus vaccine.
Li Y; Xue M; Yu L; Luo G; Yang H; Jia L; Zeng Y; Li T; Ge S; Xia N
Vaccine; 2018 Apr; 36(16):2086-2092. PubMed ID: 29555220
[TBL] [Abstract][Full Text] [Related]
7. Particle-bombardment-mediated DNA vaccination with rotavirus VP4 or VP7 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.
Choi AH; Basu M; Rae MN; McNeal MM; Ward RL
Virology; 1998 Oct; 250(1):230-40. PubMed ID: 9770437
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, antigenicity, and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5(1)* and VP8* from rhesus rotavirus.
Dunn SJ; Fiore L; Werner RL; Cross TL; Broome RL; Ruggeri FM; Greenberg HB
Arch Virol; 1995; 140(11):1969-78. PubMed ID: 7503695
[TBL] [Abstract][Full Text] [Related]
9. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles.
Herrmann JE; Chen SC; Jones DH; Tinsley-Bown A; Fynan EF; Greenberg HB; Farrar GH
Virology; 1999 Jun; 259(1):148-53. PubMed ID: 10364499
[TBL] [Abstract][Full Text] [Related]
10. Protective immunity induced by rotavirus DNA vaccines.
Chen SC; Fynan EF; Robinson HL; Lu S; Greenberg HB; Santoro JC; Herrmann JE
Vaccine; 1997 Jun; 15(8):899-902. PubMed ID: 9234543
[TBL] [Abstract][Full Text] [Related]
11. DNA immunization with a bovine rotavirus VP4 gene induces a Th1-like immune response in mice.
Suradhat S; Yoo D; Babiuk LA; Griebel P; Baca-Estrada ME
Viral Immunol; 1997; 10(3):117-27. PubMed ID: 9344334
[TBL] [Abstract][Full Text] [Related]
12. Rotavirus vaccines.
Flores J; Kapikian AZ
Biotechnology; 1992; 20():255-88. PubMed ID: 1318136
[No Abstract] [Full Text] [Related]
13. Attachment and growth of human rotaviruses RV-3 and S12/85 in Caco-2 cells depend on VP4.
Kirkwood CD; Bishop RF; Coulson BS
J Virol; 1998 Nov; 72(11):9348-52. PubMed ID: 9765487
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccines against rotavirus infections.
Herrmann JE; Chen SC; Fynan EF; Santoro JC; Greenberg HB; Robinson HL
Arch Virol Suppl; 1996; 12():207-15. PubMed ID: 9015117
[TBL] [Abstract][Full Text] [Related]
15. Isolation of a human rotavirus containing a bovine rotavirus VP4 gene that suppresses replication of other rotaviruses in coinfected cells.
Ward RL; Jin Q; Nakagomi O; Sander DS; Gentsch JR
Arch Virol; 1996; 141(3-4):615-33. PubMed ID: 8645099
[TBL] [Abstract][Full Text] [Related]
16. The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia.
Mohanty SK; Donnelly B; Lobeck I; Walther A; Dupree P; Coots A; Meller J; McNeal M; Sestak K; Tiao G
Hepatology; 2017 Apr; 65(4):1278-1292. PubMed ID: 27859498
[TBL] [Abstract][Full Text] [Related]
17. Protection against rotavirus infections by DNA vaccination.
Herrmann JE; Chen SC; Fynan EF; Santoro JC; Greenberg HB; Wang S; Robinson HL
J Infect Dis; 1996 Sep; 174 Suppl 1():S93-7. PubMed ID: 8752297
[TBL] [Abstract][Full Text] [Related]
18. Construction of four double gene substitution human x bovine rotavirus reassortant vaccine candidates: each bears two outer capsid human rotavirus genes, one encoding P serotype 1A and the other encoding G serotype 1, 2, 3, or 4 specificity.
Hoshino Y; Jones RW; Chanock RM; Kapikian AZ
J Med Virol; 1997 Apr; 51(4):319-25. PubMed ID: 9093947
[TBL] [Abstract][Full Text] [Related]
19. Amino acid sequence analysis of bovine rotavirus B223 reveals a unique outer capsid protein VP4 and confirms a third bovine VP4 type.
Hardy ME; Gorziglia M; Woode GN
Virology; 1992 Nov; 191(1):291-300. PubMed ID: 1329320
[TBL] [Abstract][Full Text] [Related]
20. Trypsin activation pathway of rotavirus infectivity.
Arias CF; Romero P; Alvarez V; López S
J Virol; 1996 Sep; 70(9):5832-9. PubMed ID: 8709201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
